

Muthiah Vaduganathan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7604998/publications.pdf>

Version: 2024-02-01

340
papers

14,293
citations

39113

52
h-index

31191

106
g-index

345
all docs

345
docs citations

345
times ranked

19494
citing authors

#	ARTICLE	IF	CITATIONS
1	Renin-Ângiotensin-Âldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1653-1659.	13.9	1,732
2	The Global Health and Economic Burden of Hospitalizations for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1123-1133.	1.2	1,640
3	Rehospitalization for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 391-403.	1.2	582
4	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet</i> , 2020, 396, 121-128.	6.3	376
5	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
6	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
7	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 76, 280-288.	1.2	259
8	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015, 12, 220-229.	6.1	238
9	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193
10	Screening and Management of Depression in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1827-1845.	1.2	182
11	Left Ventricular Thrombus After Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 642.	3.0	171
12	Clinical Outcomes in Young US Adults Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 379.	2.6	165
13	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	4.3	157
14	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020, 3, e1918962.	2.8	152
15	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. <i>JAMA Cardiology</i> , 2018, 3, 1011.	3.0	146
16	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet</i> , 2019, 393, 2155-2167.	6.3	140
17	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
18	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2162-2175.	1.2	127

#	ARTICLE	IF	CITATIONS
19	Anticoagulation Strategies in Patients With Cancer. Journal of the American College of Cardiology, 2019, 73, 1336-1349.	1.2	121
20	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 2524.	3.8	121
21	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 975-982.	1.9	111
22	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC: Heart Failure, 2019, 7, 1-12.	1.9	109
23	Thirty-Day Readmissions. JAMA - Journal of the American Medical Association, 2013, 309, 345.	3.8	102
24	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. Journal of the American College of Cardiology, 2018, 72, 3370-3372.	1.2	102
25	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC: Heart Failure, 2021, 9, 65-73.	1.9	93
26	Marijuana Use in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 320-332.	1.2	91
27	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2021, 78, 330-343.	1.2	90
28	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 750-758.	1.6	89
29	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1823-1832.	1.2	88
30	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. Journal of the American College of Cardiology, 2020, 75, 245-254.	1.2	88
31	Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. Journal of Heart and Lung Transplantation, 2019, 38, 858-869.	0.3	85
32	Response to Prasugrel and Levels of Circulating Reticulated Platelets in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 513-517.	1.2	80
33	Misclassification of Myocardial Injury as Myocardial Infarction. JAMA Cardiology, 2019, 4, 460.	3.0	80
34	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<sc>US</sc>, <sc>UK</sc> and Sweden). European Journal of Heart Failure, 2021, 23, 1499-1511.	2.9	80
35	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 862-874.	1.9	77
36	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	3.0	76

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 2020, 7, 3298-3309.	1.4	76
38	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	1.9	75
39	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.	1.6	74
40	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. European Journal of Heart Failure, 2020, 22, 472-485.	2.9	71
41	The disconnect between phase II and phase III trials of drugs for heart failure. Nature Reviews Cardiology, 2013, 10, 85-97.	6.1	69
42	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2016, 67, 1661-1671.	1.2	69
43	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602.	1.0	69
44	The Drug-Intoxication Epidemic and Solid-Organ Transplantation. New England Journal of Medicine, 2018, 378, 1943-1945.	13.9	68
45	Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. JACC: Heart Failure, 2020, 8, 640-653.	1.9	65
46	Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. JACC: Heart Failure, 2019, 7, 169-172.	1.9	64
47	Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 800-810.	1.9	64
48	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
49	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. Circulation, 2020, 142, 230-243.	1.6	59
50	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. JAMA Cardiology, 2020, 5, 1182.	3.0	59
51	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	1.9	58
52	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. Journal of the American College of Cardiology, 2013, 61, 571-579.	1.2	58
53	Sudden Death in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 653-661.	1.9	56
54	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. JACC: Heart Failure, 2020, 8, 844-855.	1.9	56

#	ARTICLE	IF	CITATIONS
55	The immunological axis in heart failure: importance of the leukocyte differential. Heart Failure Reviews, 2013, 18, 835-845.	1.7	54
56	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 OrgBT /Overlock 10 TF		
57	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. JACC: Heart Failure, 2020, 8, 347-358.	1.9	53
58	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	1.9	53
59	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
60	Type 2 Myocardial Infarction – Diagnosis, Prognosis, and Treatment. JAMA - Journal of the American Medical Association, 2018, 320, 433.	3.8	51
61	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 848-857.	1.2	50
62	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. JACC: Heart Failure, 2021, 9, 215-223.	1.9	50
63	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. Circulation, 2019, 140, 2076-2088.	1.6	49
64	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	1.7	48
65	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	1.2	48
66	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	1.2	47
67	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	47
68	Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD. Journal of the American College of Cardiology, 2019, 73, 2454-2464.	1.2	47
69	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HF with Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 469-480.	1.9	47
70	Optimizing Foundational Therapies in Patients With HF with Reduced Ejection Fraction. JACC Basic To Translational Science, 2022, 7, 504-517.	1.9	47
71	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 75, 1644-1656.	1.2	46
72	Prognostic scores in heart failure – Critical appraisal and practical use. International Journal of Cardiology, 2015, 188, 1-9.	0.8	45

#	ARTICLE	IF	CITATIONS
73	Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. <i>European Journal of Heart Failure</i> , 2021, 23, 1191-1201.	2.9	45
74	Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum. <i>Journal of the American College of Cardiology</i> , 2021, 78, 453-464.	1.2	45
75	Hemoconcentration-guided Diuresis in Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1154-1159.	0.6	43
76	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
77	Association of the New Peer Group Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e192987.	2.8	42
78	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
79	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1000.	3.0	41
80	Accelerated and personalized therapy for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2573-2587.	1.0	41
81	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 165-178.	1.4	40
82	Relation of Body Mass Index to Late Survival After Valvular Heart Surgery. <i>American Journal of Cardiology</i> , 2012, 110, 1667-1678.	0.7	39
83	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	2.9	39
84	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016, 117, 1231-1235.	0.7	38
85	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	1.2	38
86	Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2022190.	2.8	38
87	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2356-2362.	1.0	38
88	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	0.7	37
89	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2018, 131, 575-577.	0.6	37
90	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 127.	3.0	36

#	ARTICLE	IF	CITATIONS
91	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002797.	3.9	36
92	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. <i>JAMA Network Open</i> , 2021, 4, e2033994.	2.8	36
93	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	1.2	35
94	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	4.3	35
95	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
96	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
97	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	1.2	34
98	Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831.	1.6	34
99	Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2020, 5, 136.	3.0	33
100	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016, 129, 1002-1005.	0.6	32
101	Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. <i>Journal of the American Heart Association</i> , 2018, 7, e010203.	1.6	32
102	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. <i>Resuscitation</i> , 2019, 137, 205-212.	1.3	31
103	Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. <i>Stroke</i> , 2021, 52, e217-e223.	1.0	31
104	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 415-422.	0.6	29
105	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021, 36, 2532-2535.	1.3	29
106	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , 2021, 23, 1468-1476.	2.9	29
107	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013, 18, 797-813.	1.7	28
108	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405.	2.2	28

#	ARTICLE	IF	CITATIONS
109	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797.	1.6	28
110	Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span. <i>JAMA Cardiology</i> , 2020, 5, 576.	3.0	28
111	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018, 131, 956-960.	0.6	27
112	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 122.	1.2	27
113	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016, 21, 455-462.	1.7	26
114	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>American Journal of Cardiology</i> , 2019, 124, S20-S27.	0.7	26
115	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. <i>Hypertension</i> , 2019, 73, 60-67.	1.3	26
116	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	1.9	26
117	Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. <i>European Journal of Heart Failure</i> , 2021, 23, 1002-1008.	2.9	25
118	Cardio-Renal-Metabolic Care Models. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007264.	0.9	25
119	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006623.	1.6	24
120	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , 2022, 243, 103-109.	1.2	24
121	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	0.7	23
122	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	2.9	23
123	Trends in Female Authorship: A Bibliometric Analysis of The Annals of Thoracic Surgery. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1387-1393.	0.7	23
124	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	1.9	23
125	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598.	1.2	23
126	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	2.9	23

#	ARTICLE	IF	CITATIONS
127	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
128	Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179.	0.7	22
129	Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 691-693.	2.4	22
130	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018, 7, e010364.	1.6	22
131	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
132	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
133	Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 211-217.	1.0	21
134	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
135	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Medicine</i> , 2019, 132, 733-739.	0.6	21
136	Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 179-189.	1.9	21
137	Angioedema in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3283-3284.	1.0	21
138	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. <i>Journal of the American College of Cardiology</i> , 2022, 79, 432-444.	1.2	21
139	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21
140	Cangrelor Use Since FDA Approval. <i>Journal of the American College of Cardiology</i> , 2017, 69, 463-464.	1.2	20
141	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	20
142	Running thin: implications of a heparin shortage. <i>Lancet</i> , The, 2020, 395, 534-536.	6.3	20
143	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	2.9	20
144	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021, 144, 177-179.	1.6	20

#	ARTICLE	IF	CITATIONS
145	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	3.0	20
146	Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. Mayo Clinic Proceedings, 2019, 94, 776-782.	1.4	19
147	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 356-363.	1.4	19
148	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a <sc>SPRINT</sc> substudy. European Journal of Heart Failure, 2021, 23, 384-392.	2.9	19
149	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiology, 2021, 6, 1415.	3.0	19
150	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008597.	1.6	19
151	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. European Journal of Preventive Cardiology, 2017, 24, 1648-1659.	0.8	18
152	Application of the H₂FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 1288-1291.	2.9	18
153	Implications of Specialist Density for Diabetes Care in the United States. JAMA Cardiology, 2019, 4, 1174.	3.0	18
154	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. American Journal of Medicine, 2019, 132, 840-846.	0.6	18
155	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
156	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. JAMA Internal Medicine, 2020, 180, 141.	2.6	17
157	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 618-626.	1.9	17
158	Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post Hoc Analysis of the ATHENA Trial. European Journal of Heart Failure, 2022, , .	2.9	17
159	Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation, 2022, 145, 1741-1743.	1.6	17
160	Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. European Journal of Preventive Cardiology, 2014, 21, 1153-1162.	0.8	16
161	A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute Pancreatitis. Baylor University Medical Center Proceedings, 2015, 28, 466-468.	0.2	16
162	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. Journal of the American College of Cardiology, 2018, 72, 1166-1170.	1.2	16

#	ARTICLE	IF	CITATIONS
163	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 336.	3.0	16
164	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020, 223, 123-131.	1.2	16
165	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007440.	0.9	16
166	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021, 107, 1407-1416.	1.2	16
167	Death Due to Munchausen Syndrome: A Case of Idiopathic Recurrent Right Ventricular Failure and a Review of the Literature. <i>Psychosomatics</i> , 2014, 55, 668-672.	2.5	15
168	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1647-1658.	1.0	15
169	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020, 5, 515.	3.0	15
170	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 354.	3.0	15
171	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
172	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	1.7	15
173	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. <i>ESC Heart Failure</i> , 2022, 9, 947-952.	1.4	15
174	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <sc>PARAGONâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 794-803.	2.9	15
175	<sc>Angiotensinâ€neprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
176	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009099.	1.6	14
177	Epidemiology of Hospitalized Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 271-276.	1.0	13
178	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020, 43, 2684-2690.	4.3	13
179	Thirty-Day Nonindex Readmissions and Clinical Outcomes After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2020, 110, 484-491.	0.7	13
180	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007492.	0.9	13

#	ARTICLE	IF	CITATIONS
181	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 1583-1594.	2.9	13
182	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
183	Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671.	2.9	12
184	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346.	0.7	12
185	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq1 1 0.784314,rgBT /Overlock 10	0.7	12
186	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019, 380, 597-599.	13.9	12
187	Emerging Trends in Financing of Adult Heart Transplantation in the United States. <i>JACC: Heart Failure</i> , 2019, 7, 56-62.	1.9	12
188	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
189	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006638.	1.6	12
190	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <sc>EMPA-REG OUTCOME</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	2.2	12
191	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850.	0.7	11
192	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <sc>PARADIGM-HF</sc> analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1346-1356.	2.9	11
193	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. <i>JACC: Heart Failure</i> , 2022, 10, 1-11.	1.9	11
194	Health Status Trajectories Before and After Hospitalization for Heart Failure. <i>Circulation</i> , 2022, 145, 1872-1874.	1.6	11
195	Drug Therapy to Reduce Early-Readmission-Risk in Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 361-364.	1.9	10
196	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
197	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	10
198	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 359-361.	0.7	10

#	ARTICLE	IF	CITATIONS
199	Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 235-237.	2.9	10
200	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-“Lowering Therapies Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2021, 6, 92-96.	3.0	10
201	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2517-2521.	1.2	10
202	Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019. <i>Journal of the American Heart Association</i> , 2021, 10, e022644.	1.6	10
203	Validation of the WATCH-DM and TRS-HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	10
204	Midterm Benefits of Preoperative Statin Therapy in Patients Undergoing Isolated Valve Surgery. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1881-1887.	0.7	9
205	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016, 18, 128-132.	2.9	9
206	Angiotensin-Nepriylsin Inhibition as a Paradigm for All?. <i>Current Cardiology Reports</i> , 2016, 18, 115.	1.3	9
207	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	0.8	9
208	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017, 241, 423-429.	0.8	9
209	Design and rationale of the North Indian ST-“Segment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019, 42, 1140-1146.	0.7	9
210	Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. <i>European Journal of Heart Failure</i> , 2020, 22, 422-424.	2.9	9
211	Training the Next Generation of Cardiometabolic Specialists. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1233-1237.	1.2	9
212	Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes-“Findings from the Look AHEAD Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 2489-2497.	1.7	9
213	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2013, 1, 123-126.	1.9	8
214	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1763-1769.	0.7	8
215	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
216	Large-Volume Barium Aspiration. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 183-184.	0.2	8

#	ARTICLE	IF	CITATIONS
217	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	8
218	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
219	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	1.2	8
220	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	1.4	8
221	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	1.7	7
222	Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e200181.	2.8	7
223	Trends, Management, and Outcomes of Acute Myocardial Infarction Hospitalizations With In-Hospital Onset Versus Out-of-Hospital Onset: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021, 10, e018414.	1.6	7
224	Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States. <i>Journal of Cardiac Failure</i> , 2021, 27, 1280-1284.	0.7	7
225	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1242-1253.	1.2	7
226	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>International Journal of Cardiology</i> , 2021, 323, 188-191.	0.8	7
227	Physician Practice Pattern Variations in Common Clinical Scenarios Within 5 US Metropolitan Areas. <i>JAMA Health Forum</i> , 2022, 3, e214698.	1.0	7
228	The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. <i>Journal of Invasive Cardiology</i> , 2020, 32, E130-E132.	0.4	7
229	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 861-866.	2.9	7
230	The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 883-892.	0.7	7
231	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018, 15, 10-16.	1.3	6
232	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14	0.7	6
233	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
234	Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. <i>Circulation: Heart Failure</i> , 2020, 13, e007070.	1.6	6

#	ARTICLE	IF	CITATIONS
235	Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. <i>American Journal of Medicine</i> , 2020, 133, 525-527.	0.6	6
236	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021, 8, 26-36.	1.4	6
237	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
238	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021, 6, 1432.	3.0	6
239	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 97-98.	1.6	6
240	Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery. <i>Journal of Cardiac Failure</i> , 2022, 28, 330-333.	0.7	6
241	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <sc>PARAGON</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	2.9	6
242	Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2022, 45, 1549-1557.	4.3	6
243	Expanding the Scope of the "Polypill" to Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 540-541.	0.7	5
244	Modern Drug Development. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2619.	3.8	5
245	Simultaneous Platelet P2Y ₁₂ and P2Y ₁ ADP Receptor Blockade. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 427-428.	1.1	5
246	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 944-954.	1.3	5
247	Wake Forest University long-term follow-up of type 2 myocardial infarction: The WakeUP T2MI Registry. <i>Clinical Cardiology</i> , 2019, 42, 592-604.	0.7	5
248	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1660-1666.	0.7	5
249	How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?. <i>JACC: Heart Failure</i> , 2020, 8, 67-69.	1.9	5
250	Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100172.	1.3	5
251	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans' Health Administrative Database. <i>CardioRenal Medicine</i> , 2021, 11, 226-236.	0.7	5
252	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure. <i>JACC: CardioOncology</i> , 2020, 2, 710-718.	1.7	5

#	ARTICLE	IF	CITATIONS
253	Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. <i>Journal of Cardiac Failure</i> , 2022, 28, 1035-1039.	0.7	5
254	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E12-E14.	1.4	5
255	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. <i>Heart Failure Reviews</i> , 2014, 19, 695-698.	1.7	4
256	Metastatic Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotrophic Hormone Production. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 46-49.	0.2	4
257	A roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015, 65, 26-31.	0.8	4
258	Preparing Fellows for Precision Cardiology. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1675-1679.	1.2	4
259	Expanding the global borders of heart failure: the SHOP and PEOPLE studies. <i>European Heart Journal</i> , 2018, 39, 1781-1783.	1.0	4
260	Developing evidence-based and accountable health policy in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1653-1656.	2.9	4
261	Epirubicin and long-term heart failure risk in breast cancer survivors. <i>European Journal of Heart Failure</i> , 2018, 20, 1454-1456.	2.9	4
262	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. <i>Heart Failure Clinics</i> , 2020, 16, 433-440.	1.0	4
263	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. <i>Current Diabetes Reports</i> , 2020, 20, 63.	1.7	4
264	Citizenship Status and Cardiothoracic Organ Transplantation in the United States. <i>Circulation: Heart Failure</i> , 2020, 13, e007788.	1.6	4
265	Extensive Arterial Thrombosis in Covid-19. <i>American Journal of Cardiology</i> , 2020, 134, 148-149.	0.7	4
266	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	1.3	4
267	Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2021, 156, 140-142.	0.7	4
268	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022, 346, 30-34.	0.8	4
269	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
270	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4

#	ARTICLE	IF	CITATIONS
271	Guideline based eligibility for primary prevention statin therapy â€“ Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). Journal of Clinical Lipidology, 2021, , .	0.6	4
272	Progress or lack of progress in hospitalized heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 1079-1083.	0.6	3
273	Classification of Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 277-283.	1.0	3
274	Ping-Pong Gaze. New England Journal of Medicine, 2015, 372, e34.	13.9	3
275	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Failure Reviews, 2015, 20, 393-400.	1.7	3
276	Revisiting the Clopidogrelâ€“Proton Pump Inhibitor Interaction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	3
277	Hospitalized Heart Failure in the United States. Heart Failure Clinics, 2015, 11, 591-601.	1.0	3
278	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. Current Heart Failure Reports, 2017, 14, 203-209.	1.3	3
279	Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. European Journal of Heart Failure, 2019, 21, 1267-1269.	2.9	3
280	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 62-71.	1.8	3
281	Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 177-179.	1.8	3
282	Angiotensin receptorâ€“neprilysin inhibition in heart failure with preserved ejection fraction: lessons from <sc>PARAGONâ€“HF</sc>. European Journal of Heart Failure, 2020, 22, 1525-1530.	2.9	3
283	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e38-e40.	1.4	3
284	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53.	1.2	3
285	Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. JACC: Cardiovascular Interventions, 2021, 14, 1757-1767.	1.1	3
286	Serum Potassium and Mortality in High-Risk Patients: SPRINT. Hypertension, 2021, 78, 1586-1594.	1.3	3
287	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 1267-1277.	0.7	3
288	Torus Palatinus. Baylor University Medical Center Proceedings, 2014, 27, 259-259.	0.2	2

#	ARTICLE	IF	CITATIONS
289	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. American Journal of Medicine, 2014, 127, 574-578.	0.6	2
290	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). American Journal of Cardiology, 2015, 116, 307-312.	0.7	2
291	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. International Journal of Cardiology, 2016, 214, 16-18.	0.8	2
292	One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). American Journal of Cardiology, 2016, 118, 1111-1116.	0.7	2
293	<i>De novo</i> heart failure: where the journey begins. European Journal of Heart Failure, 2019, 21, 1245-1247.	2.9	2
294	Adoption of hepatitis C virusâ€“infected donor hearts: A â€œmiddle childâ€“no more. Journal of Heart and Lung Transplantation, 2019, 38, 918-919.	0.3	2
295	Transforming the interpretation of significance in heart failure trials. European Journal of Heart Failure, 2020, 22, 177-180.	2.9	2
296	Angiotensinâ€“neprilysin inhibition in <i>de novo</i> heart failure â€“ starting off strong. European Journal of Heart Failure, 2020, 22, 313-314.	2.9	2
297	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. Current Opinion in Cardiology, 2020, 35, 517-523.	0.8	2
298	Orphan Drug Development in Cardiovascular Medicine. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006509.	0.9	2
299	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298â€“2306. Diabetes Care, 2020, 43, e26-e27.	4.3	2
300	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	0.7	2
301	<sc>OUTSTEPâ€“HF</sc>: reâ€“evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 2021, 23, 136-139.	2.9	2
302	The Intersection of Type 2 Myocardial Infarction and Heart Failure. Journal of the American Heart Association, 2021, 10, e020849.	1.6	2
303	Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	2
304	Dual Antiplatelet Therapy After Stent Implantation. JAMA - Journal of the American Medical Association, 2014, 311, 1446.	3.8	1
305	In Reply to Loh and Lin. Academic Medicine, 2014, 89, 530.	0.8	1
306	Coronary stenting approaches in the treatment of chronic total occlusion. Journal of Cardiovascular Medicine, 2016, 17, 673-679.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Stroke prevention in heart failure and sinus rhythm: where do we go from here?. <i>European Journal of Heart Failure</i> , 2016, 18, 1267-1269.	2.9	1
308	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. <i>International Journal of Cardiology</i> , 2018, 252, 214-215.	0.8	1
309	Moving Beyond the Hospital. <i>Circulation</i> , 2018, 138, 2169-2171.	1.6	1
310	Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 875-877.	0.6	1
311	Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era—Reply. <i>JAMA Cardiology</i> , 2018, 3, 1129.	3.0	1
312	Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope. <i>American Journal of Medicine</i> , 2018, 131, e451-e453.	0.6	1
313	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 7, e35-e37.	1.4	1
314	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2574-2575.	1.2	1
315	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , 2021, 26, 11-21.	1.7	1
316	Neprilysin and Corin. <i>JACC: Heart Failure</i> , 2021, 9, 96-99.	1.9	1
317	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	1.7	1
318	Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization?. <i>Journal of Cardiac Failure</i> , 2021, 27, 910-912.	0.7	1
319	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021, 158, 59-65.	0.7	1
320	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021, , CIRCHEARTFAILURE121008403.	1.6	1
321	A Heart Team approach to contemporary device decision-making in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 562-564.	2.9	1
322	Sudden Flare of Rheumatoid Arthritis Associated with Newly Diagnosed Atrial Flutter. <i>Baylor University Medical Center Proceedings</i> , 2014, 27, 233-234.	0.2	0
323	Acute Lymphocytic Leukemia with Superimposed Invasive Aspergillosis and Pneumopericardium Successfully Treated with Voriconazole. <i>Baylor University Medical Center Proceedings</i> , 2014, 27, 250-252.	0.2	0
324	Influence of Chronic Kidney Disease on Warfarin Therapy for Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2541.	3.8	0

#	ARTICLE	IF	CITATIONS
325	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 123-131.	0.6	0
326	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e389-e390.	0.6	0
327	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e263.	0.6	0
328	Navigating Data Sharing in Cardiology From a Trainee's Perspective. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2075-2078.	1.2	0
329	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e267-e268.	0.6	0
330	Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?. <i>IJC Heart and Vasculature</i> , 2019, 24, 100404.	0.6	0
331	Electrocardiography and left ventricular function: looking beyond hypertrophy. <i>Hypertension Research</i> , 2019, 42, 580-582.	1.5	0
332	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 128, 113-119.	0.7	0
333	Discovery and care innovation amidst a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 2202-2204.	2.9	0
334	Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1638-1640.	2.9	0
335	Considering dose in pharmacological therapies for heart failure – Authors' reply. <i>Lancet</i> , The, 2021, 397, 275.	6.3	0
336	Addressing Equity and More in 2021. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1372-1373.	1.2	0
337	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021, 27, 1027-1030.	0.7	0
338	Modifiable Risk Factor Burden Among 3 Different Age Groups with Heart Failure. <i>American Journal of Cardiology</i> , 2021, 156, 150-152.	0.7	0
339	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines heart failure participating centers. <i>American Heart Journal</i> , 2022, 246, 1-11.	1.2	0
340	Implementation of Cardiometabolic Centers and Training Programs. <i>Current Diabetes Reports</i> , 2022, , 1.	1.7	0